Crosspoint Capital Strategies’s Vertex Pharmaceuticals VRTX Stock Holding History

Crosspoint Capital Strategies’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	$1.22M	Buy	+4,229	New	+$1.29M	2.42%	24

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Crosspoint Capital Strategies's VRTX Position: Q4 2022 in Review

Crosspoint Capital Strategies opened a new position in Vertex Pharmaceuticals (VRTX) in Q4 2022: 4,229 shares worth $1.22M. The stake represents 2.42% of the portfolio and ranks #24 among its holdings.

1,222 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

Crosspoint Capital Strategies held 4,229 shares of Vertex Pharmaceuticals worth $1.22M as of Q4 2022.
Vertex Pharmaceuticals was a new Crosspoint Capital Strategies position in Q4 2022.
Vertex Pharmaceuticals made up 2.42% of Crosspoint Capital Strategies's portfolio in Q4 2022, its #24 holding.
1,222 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Crosspoint Capital Strategies's 13F filing for Q4 2022, filed 13 Feb 2023.